See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/356753059

### Creatine supplementation and VO2max: a systematic review and metaanalysis

Article in Critical Reviews In Food Science and Nutrition · December 2021

DOI: 10.1080/10408398.2021.2008864

CITATION	S	READS	
5		1,362	
9 autho	rs, including:		
	Damien Gras		Charlotte Lanhers
E.	Université Clermont Auvergne		Centre Hospitalier Universitaire de Clermont-Ferrand
	1 PUBLICATION 5 CITATIONS		35 PUBLICATIONS 493 CITATIONS
	SEE PROFILE		SEE PROFILE
	Reza Bagheri		Ukadike Chris Ugbolue
	University of Isfahan		University of the West of Scotland
	124 PUBLICATIONS 1,324 CITATIONS	_	95 PUBLICATIONS 803 CITATIONS
	SEE PROFILE		SEE PROFILE





**Critical Reviews in Food Science and Nutrition** 

ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/bfsn20

## Creatine supplementation and VO<sub>2</sub>max: a systematic review and meta-analysis

Damien Gras, Charlotte Lanhers, Reza Bagheri, Ukadike Chris Ugbolue, Emmanuel Coudeyre, Bruno Pereira, Marek Zak, Jean-Baptiste Bouillon-Minois & Frédéric Dutheil

To cite this article: Damien Gras, Charlotte Lanhers, Reza Bagheri, Ukadike Chris Ugbolue, Emmanuel Coudeyre, Bruno Pereira, Marek Zak, Jean-Baptiste Bouillon-Minois & Frédéric Dutheil (2021): Creatine supplementation and VO<sub>2</sub>max: a systematic review and meta-analysis, Critical Reviews in Food Science and Nutrition, DOI: 10.1080/10408398.2021.2008864

To link to this article: https://doi.org/10.1080/10408398.2021.2008864



View supplementary material 🖸

4		0
П	Т	П
_	_	_

Published online: 03 Dec 2021.



Submit your article to this journal



💽 View related articles 🗹

🌔 🛛 View Crossmark data 🗹

#### REVIEW

Taylor & Francis Taylor & Francis Group

Check for updates

# Creatine supplementation and VO<sub>2</sub>max: a systematic review and meta-analysis

Damien Gras<sup>a</sup>, Charlotte Lanhers<sup>a</sup> (), Reza Bagheri<sup>b</sup> (), Ukadike Chris Ugbolue<sup>c</sup> (), Emmanuel Coudeyre<sup>d</sup> (), Bruno Pereira<sup>e</sup> (), Marek Zak<sup>f</sup> (), Jean-Baptiste Bouillon-Minois<sup>g</sup> () and Frédéric Dutheil<sup>h</sup> ()

<sup>a</sup>CHU Clermont–Ferrand, Physical and Rehabilitation Medicine, Université Clermont Auvergne, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France; <sup>b</sup>Department of Exercise Physiology, University of Isfahan, Isfahan, Iran; <sup>c</sup>University of the West of Scotland, School of Health and Life Sciences, Institute for Clinical Exercise & Health Science, South Lanarkshire, Scotland, UK; <sup>d</sup>INRAE, Human Nutrition Unit (UNH), Université Clermont Auvergne, University Hospital of Clermont-Ferrand, CHU Clermont-Ferrand, Physical and Rehabilitation Medicine, Clermont-Ferrand, France; <sup>e</sup>CHU Clermont-Ferrand, Biostatistics, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France; <sup>f</sup>Faculty of Medicine and Health Sciences, Institute of Physiotherapy, The Jan Kochanowski University, Kielce, Poland; <sup>g</sup>Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, CHU Clermont-Ferrand, Emergency Medicine, Clermont-Ferrand, France; <sup>h</sup>Université Clermont Auvergne, CNRS, LaPSCo, Physiological and Psychosocial Stress, University Hospital of Clermont-Ferrand, CHU Clermont-Ferrand, Occupational and Environmental Medicine, WittyFit, Clermont-Ferrand, France

#### ABSTRACT

Although creatine supplementation is well-known to increase exercise performance in acute high-intensity exercises, its role in aerobic performance based on VO<sub>3</sub>max is more controversial. Thus, we performed a systematic review and meta-analysis on the effects of creatine supplementation on VO<sub>2</sub>max. PubMed, Cochrane, Embase, and ScienceDirect were searched for randomized controlled trials (RCTs) reporting VO, max in creatine supplementation and placebo groups before and after supplementation. We computed a random-effects meta-analysis on VO<sub>2</sub>max at baseline, within groups following supplementation, on changes on VO<sub>2</sub>max between groups, and after supplementation between groups. Sensitivity analyses and meta-regression were conducted. We included 19 RCTs for a total of 424 individuals (mean age 30 years old, 82% men). VO<sub>2</sub>max did not differ at baseline between groups (creatine and placebo). Participants in both groups were engaged in exercise interventions in most studies (80%). Using changes in VO,max, VO,max increased in both groups but increased less after creatine supplementation than placebo (effect size [ES] = -0.32, 95%CI = -0.51 to -0.12, p = 0.002). Comparisons after creatine supplementation confirmed a lower VO<sub>2</sub>max in the creatine group compared to the placebo group (ES= -0.20, 95%Cl = -0.39 to -0.001, p = 0.049). Meta-analysis after exclusion from meta-funnel resulted in similar outcomes in a subgroup of young and healthy participants. Meta-regressions on characteristics of supplementation, physical training, or sociodemographic were not statistically significant. Creatine supplementation has a negative effect on VO<sub>2</sub>max, regardless of the characteristics of training, supplementation, or population characteristics.

#### **KEYWORDS**

Dietary supplement; endurance; cardiorespiratory fitness; VO<sub>2</sub>peak; ventilatory threshold

#### Introduction

Creatine (Cr) is known as one of the most popular sport dietary supplements on the market, which is widely used among recreational and professional athletes, with more than \$400 million in annual sales (Momaya, Fawal, and Estes 2015). The popularity of Cr supplementation (CS) can be explained by intensive marketing about its ergogenic effects, particularly in sports performance. It's primarily admitted that CS improves performance in acute and high-intensity exercises such as sprints (Dawson et al. 1995) and muscle strength (Lanhers et al. 2015; Lanhers et al. 2017) and has health and potential therapeutic benefits (Kreider and Stout 2021). Despite this, the current scientific literature diverges on its potential effects on endurance performance (Engelhardt et al. 1998; Preen et al. 2001). The gold standard to assess endurance capacities is  $VO_2max$  ("VO2 Max – an Overview | ScienceDirect Topics" 2021).  $VO_2max$  is defined as the oxygen uptake attained during maximal exercise intensity that could not be increased despite further increases in exercise workload (Hill and Lupton 1923).  $VO_2$  is the oxygen flow taken by the lungs, transported through the blood circulation coupled with hemoglobin, and used to oxidation of energy substrates (glucose and fatty acids) in the respiratory chain of mitochondria resulting in Adenosine triphosphate (ATP) resynthesis (Bassett 2000). It was demonstrated that  $VO_2max$  is a valid index measuring the

limits of the cardiorespiratory system (Hawkins et al. 2007) and also is one of the main outcomes that can predict performance in endurance sport. The increase in  $VO_2max$  following training results primarily from an increase in maximal cardiac output (Lanferdini et al. 2020; Kipp, Kram, and Hoogkamer 2019).

Moreover, the assessment of VO<sub>2</sub>max through an incremental exercise test seems to be one of the most reproducible measurements, irrespective of the protocols used (Chidnok et al. 2013). Some studies have investigated the effect of CS on VO<sub>2</sub>max (Balsom et al. 1993; Nelson et al. 2000). The ATP energy supply by the energy-rich phosphate bond of phosphocreatine (CrP) occurs during the first seconds of a high-intensity exercise in anaerobic conditions due to the limited CrP stores requiring a recovery period of several minutes before its regeneration (Gastin 2001). In prolonged efforts, Cr could interact with aerobic metabolism through several lesser-known mechanisms with a Cr phosphate shuttle facilitating the ATP transport from the mitochondria to the cytosol within the cell needing ATP for muscle contraction (Wallimann, Tokarska-Schlattner, and Schlattner 2011). It also has a role in increasing glycogen storage with an increase in GLUT4 transporters (Ju et al. 2005; Eijnde et al. 2001) and changes in cell volume with the osmotic effect of Cr (Loon et al. 2004). In addition to its role in the regulation and homeostasis of energy metabolism, CS could improve muscle activation (Da Silva Azevedo et al. 2019) and VO<sub>2</sub> kinetics at the same workloads (Murphy et al. 2005; Hickner et al. 2010), which may be beneficial for endurance performance. Besides its common use in sports, CS has also been evaluated in the elderly and certain pathological conditions (Canete et al. 2006; Carvalho et al. 2012). Despite these considerations, the effects of CS on aerobic performance remain uncertain. To date, no meta-analysis study has specifically focused on its effects on changes in VO<sub>2</sub>max.

Thus, we aimed to conduct a systematic review and meta-analysis of all randomized controlled trials (RCTs) comparing the effects of CS versus placebo on VO<sub>2</sub>max. Secondary aims were to determine the influence of population characteristics, supplementation, and physical training associated with VO<sub>2</sub>max and assess the effects of CS on aerobic measures associated with VO<sub>2</sub>max during incremental exercise tests (Poole and Jones 2017).

#### Materials and methods

#### Literature search

We searched for all RCTs with CS versus placebo, with a measure of  $VO_2max$  before and after supplementation. PubMed, The Cochrane Central Register of Controlled Trials (CENTRAL), Excerpta Medica Database (EMBASE), and ScienceDirect were searched until March 16th 2021, using the keywords " $VO_2max$ " AND "creatine supplementation" (see detailed search strategy in Appendix S1). The search was not limited to specific years. No language restrictions were applied. Reference lists of all publications meeting the inclusion criteria were manually searched to identify any further studies not found through electronic searching. Two authors (DG and CL) conducted all literature searches, separately reviewed and collated the abstracts, and decided the suitability of the articles for inclusion based on the selection criteria. A third author (FD) was asked to review the articles when consensus on suitability was not met. Then, all authors reviewed the eligible articles (Figure 1). We followed the PRISMA guidelines (Appendix S7).

#### **Data collection**

The data collection included the first author's name, publication year, study design, periods of studies, aims and outcomes of included articles, sample size, characteristics of individuals (age, gender, physical activity, and health status), supplementation protocol (type of Cr, total time of supplementation, and total dose), physical training during supplementation period, VO<sub>2</sub>max (values in each unit, and measurement method), and performance associated with the incremental tests (ventilatory threshold, time to exhaustion, and/or maximal power output).

#### Outcomes

The main outcome for our meta-analysis was  $VO_2max$ . Our secondary outcomes were ventilatory threshold, time to exhaustion, and maximal power output from incremental exercise tests if measures were available.



Figure 1. Search strategy.

#### Quality of assessment

The Scottish Intercollegiate Guidelines Network (SIGN) checklist for RCTs was used to assess the quality of reporting (Figure 2) ("Scottish Intercollegiate Guidelines Network Sign 50: A Guideline Developer's Handbook. [(Accessed on 1 August 2019)]; Available Online: http://www.Sign.Ac.Uk"). Through 11 items, the SIGN checklist evaluates internal validity and study quality. Additionally, the PEDro scale was assessed for each study (Appendix S2) ("PEDro Scale for Randomized Controlled Trials; Available Online: https:// Pedro.Org.Au/"). The methodological quality of the articles was evaluated by two independent reviewers.

#### Statistical considerations

Data were analyzed using Stata (version 16, TX, USA). When not available, standard deviation (SD) was calculated by multiplying the standard error of the mean (SEM) by the square root of the sample size (Lee, In, and Lee 2015) or estimated from interval quartiles or minimum and maximum intervals (Wan et al. 2014). The main meta-analysis compared changes in VO2max between groups (CS versus placebo). Changes were calculated using the method from Borenstein et al. (2009). Results were expressed as effect size (ES) (DerSimonian and Laird 1986). A decreased ES denoted a lower improvement in VO<sub>2</sub>max in the CS compared to the placebo group. A scale for ES has been suggested with -0.2 reflecting a small effect, -0.5 a moderate effect, and -0.8 a large effect (Cohen 1988). In order to verify the strength of our results, we also computed random-effects meta-analysis on VO2max (1) at baseline between groups (CS versus placebo) to verify that groups were comparable, (2) within groups after supplementation, (3) as well as after supplementation between groups. Each meta-analysis was stratified by type of exercise (running,

		Internal validity						0	Overall quality		
	Appropriate and clearly focused question	Assignment of subjects is randomised	Adequate concealment method is used	Subjects and investigators blind about treatment	Treatment and control groups are similar	Only difference between group is treatment	Outcomes measured in a standard and valid way	Number of dropped outs (%)	Analyses in randomly allocated groups	Results are comparable for all sites	General level of evidence
Balsom 1993	+	+	+	+	÷	+	+	0	+	NA	++
Barnett 1996	+	?	?	+	+	+	+	0	+	NA	++
Canete 2006	+	?	+	•	+	+	+	0	+	NA	++
Carvalho 2012	+	?	+	+	+	+	+	0	+	NA	++
Da Silveira 2014	+	?	?	+	+	+	•	8	+	NA	+
Eijnde 2003	+	?	+	+	+	+	+	0	+	NA	++
Forbes 2017	+	+	+	+	+	+	+	6	+	NA	++
Graef 2009	+	?	?	+	+	+	+	0	+	NA	++
Hickner 2010	+	?	?	+	+	+	+	0	+	NA	++
Kresta 2014	+	?	?	+	+	+	+	9	+	NA	++
Kuethe 2006	+	?	?	+	+	+	+	35	+	NA	+
Lawrence 1996	+	?	?	+	+	+	+	0	+	NA	++
Murphy 2005	+	?	?	+	+	+	+	0	+	NA	++
Nelson 2000	+	?	?	+	+	+	+	28	+	NA	+
Reardon 2006	+	?	?	•	+	+	+	23	+	NA	+
Smith 2011	+	?	?	+	+	+	+	0	+	NA	++
Sterkowicz 2012	+	?	?	+	•	+	+	0	+	NA	+
Van Loon 2003	+	+	+	+	+	+	+	5	+	NA	++
Villanueva 2014	+	?	?	+	+	+	•	0	+	NA	+

cycling, or rowing) and units of measurement (L/min or mL/kg/min). For studies that reported VO<sub>2</sub>max in both units (L/min and mL/kg/min) simultaneously, we computed meta-analyses including both units (where the weight of studies would need ponderation), and sensitivity analyses, i.e., meta-analyses using only data in L/min or mL/kg/min when both units were available within the same study. Finally, we also conducted meta-analyses on the ventilatory threshold, maximal power output, and time to exhaustion on the incremental exercise tests. For all aforementioned meta-analyses, sensitivity analyses were conducted after excluding studies outside funnel plots and on young and healthy individuals. Heterogeneity between studies was also evaluated using  $I^2$  statistic, ranging from 0 (no heterogeneity) to 100% (high heterogeneity). Meta-regressions were computed to search for putative influential factors of VO<sub>2</sub>max, such as characteristics of the population (age, gender, training, and health), characteristics of supplementation (loading dose, total duration of supplementation, and total dose), and characteristics of training during supplementation (none, aerobic, or anaerobic). Results were expressed as regression coefficients and 95%CI. P-values less than 0.05 were considered statistically significant.

#### Results

An initial search produced a possible 4985 articles. Removal of duplicates and use of the selection criteria reduced the number of articles reporting  $VO_2max$  assessment at baseline and following CS or placebo in nineteen articles. Among them, one study reported two independent gender groups (Smith et al. 2011). All articles were written in English (Figure 1).

#### **Quality of articles**

The risk of bias in included studies was mostly low (Figure 2 and Appendix S2). However, most studies did not describe the randomization method. Some studies matched participants based on the baseline measurements. Two studies used a single-blind design (Reardon et al. 2006; Canete et al. 2006), but all participants were blinded to supplementation. Three studies declared a dropout of more than twenty percent (Nelson et al. 2000; Reardon et al. 2006; Kuethe et al. 2006). All studies mentioned ethical approval.

#### Study designs and aims of included articles

All studies were double-blind, randomized placebo-controlled trials. Only one study had a cross-over design (Kuethe et al. 2006). All the studies were monocentric. Five studies were conducted in Europe (Germany (Kuethe et al. 2006), Netherlands (Van Loon et al. 2003; Bert O. Eijnde et al. 2003), Poland (Sterkowicz et al. 2012) and Sweden (Balsom et al. 1993)), one in Brazil (Carvalho et al. 2012; Lázaro da Silveira et al. 2014), eight in North America (Canada (Forbes et al. 2017) and USA (Graef et al. 2009; Hickner et al. 2010; Kresta et al. 2014; Nelson et al. 2000; Smith

et al. 2011; Canete et al. 2006; Villanueva, He, and Schroeder 2014)), and four in Australia (Barnett, Hinds, and Jenkins 1996; Lawrence et al. 1997; Murphy et al. 2005; Reardon et al. 2006). The duration between baseline and after supplementation ranged from 4 (Barnett, Hinds, and Jenkins 1996) to 180 days (Carvalho et al. 2012). The nineteen included studies aimed to evaluate the effect of CS on performance or quality of life in elderly and patients with heart failure (Canete et al. 2006; Carvalho et al. 2012; Kuethe et al. 2006; Villanueva, He, and Schroeder 2014), among which nine studies aimed specifically at assessing aerobic performance (Balsom et al. 1993; Nelson et al. 2000; Murphy et al. 2005; Hickner et al. 2010; Smith et al. 2011; Reardon et al. 2006; Forbes et al. 2017; Graef et al. 2009; Lawrence et al. 1997). Seventeen studies recruited healthy individuals, while two studies recruited patients with heart failure (Carvalho et al. 2012; Kuethe et al. 2006) (Table 1).

#### Population

The sample size ranged from 10 (Sterkowicz et al. 2012) to 46 (Eijnde et al. 2003), for a total of 424 participants (216 in the CS and 208 in the placebo group).

Gender was reported in all studies. The mean proportion of males was 81.7%, with 160 males and 56 females in the CS group versus 155 males and 53 females in the placebo group. Eleven studies included only males (Balsom et al. 1993; Barnett, Hinds, and Jenkins 1996; Lázaro da Silveira et al. 2014; Graef et al. 2009; Hickner et al. 2010; Murphy et al. 2005; Van Loon et al. 2003; Eijnde et al. 2003; Carvalho et al. 2012; Villanueva, He, and Schroeder 2014) and three only females (Canete et al. 2006; Forbes et al. 2017; Kresta et al. 2014).

Age was reported as the mean value in all studies except for three studies that reported age in the min-max interval (Balsom et al. 1993; Lázaro da Silveira et al. 2014; Reardon et al. 2006). The mean age was 29.7 years old, ranging from 20.5 (Barnett, Hinds, and Jenkins 1996) to 68 (Canete et al. 2006). Most studies (79%) had participants aged between 18 and 40 years old.

Physical activity at baseline was reported in all studies. We classified individuals as competitive or highly trained athletes (15.6%) (Sterkowicz et al. 2012; Balsom et al. 1993; Lázaro da Silveira et al. 2014; Lawrence et al. 1997), recreationally trained (54.2%) (Barnett, Hinds, and Jenkins 1996; Forbes et al. 2017; Graef et al. 2009; Hickner et al. 2010; Kresta et al. 2014; Murphy et al. 2005; Nelson et al. 2000; Reardon et al. 2006; Smith et al. 2011; Villanueva, He, and Schroeder 2014), and sedentary or have low daily physical activity (30.2%) (Van Loon et al. 2003; Bert O. Eijnde et al. 2003; Canete et al. 2006; Kuethe et al. 2006; Carvalho et al. 2012).

Additional outcomes were seldomly reported, such as echocardiographic measures (Murphy et al. 2005; Kuethe et al. 2006) or cellular changes using muscular biopsy (Hickner et al. 2010; Reardon et al. 2006; Van Loon et al. 2003; Eijnde et al. 2003; Kresta et al. 2014) (Table 1). Twelve

		6.										
			Population				-	ntervention			VO <sub>2</sub> assessr	nent
					Physical activity			g/day – n/	day – n days	Total		VO <sub>2</sub> max
Study	Country	ч	%Men	Age	level	Training	Type Cr	Loading dose	Maintenance dose	dose	Exercise test	or VO <sub>2</sub> peak
Balsom et al. (1993)	Sweden	14	100	19–37	Competition (runners)	Aerobic	Cr monohydrate	0	5-1-6	30	Treadmill	VO <sub>2</sub> peak
Barnett, Hinds, and Jenkins (1996)	Australia	17	100	20.5	Recreation	Aerobic	Cr monohydrate	0	5 - 4 - 4	20	Bicycle ergometer	VO <sub>2</sub> peak
Canete et al. (2006)	USA	16	0	68	Sedentary	None	Cr monohydrate	19 - 3 - 7	0	130	Bicycle ergometer	VO <sub>2</sub> peak
Carvalho et al. (2012)	Brazil	33	100	55.7	Sedentary (heart failure)	None	NA	0	5 - 1 - 180	006	Bicycle ergometer	VO <sub>2</sub> peak
Lázaro da Silveira et al. (2014)	Brazil	22	100	18-30	Competition (military)	Aerobic (MTP)	Cr monohydrate	25 – 3 – 7	2,5-1 - 86	385	Cooper test	estimated
Eijnde et al. (2003)	Netherlands	46	100	55-75	Sedentary	Aerobic (FTP)	Cr monohydrate	0	5 - 5 - 182	910	Bicycle ergometer	VO,peak
Forbes et al. (2017)	Canada	17	0	23	Recreation	Anaerobic (HIIT)	Cr monohydrate	19 - 2 - 5	6,5-1-23	245	Bicycle ergometer	VO <sub>2</sub> peak
Graef et al. (2009)	USA	33	100	22.6	Recreation	Anaerobic (HIIT)	Cr citrate	0	10 - 2 - 30	300	Bicycle ergometer	VO <sub>2</sub> peak
Hickner et al. (2010)	USA	12	100	27.2	Recreation (cyclists)	Aerobic	Cr monohydrate	0	3 - 1 - 28	84	Bicycle ergometer	VO <sub>2</sub> max
Kresta et al. (2014)	USA	15	0	21.5	Recreation	Aerobic	Cr monohydrate	18 - 4 - 7	6 - 1 - 21	252	Bicycle ergometer	VO,peak
Kuethe et al. (2006)	Germany	13	75	58.2	Sedentary	None	NA	20 - 4 - 42	0	840	Treadmill	estimated
					(neart failure)							
Lawrence et al. (1997)	Australia	20	50	21.2	Competition (rowers)	Aerobic	Cr monohydrate	18 – 4 – 5	0	92	Rowing ergometer	VO <sub>2</sub> peak
Murphy et al. (2005)	Australia	18	100	24	Recreation	Aerobic	Cr monohydrate	20 - 4 - 7	10 - 2 - 21	350	Bicycle ergometer	VO <sub>2</sub> max
					(team sports)							
Nelson et al. (2000)	USA	36	55	23.5	Recreation	Aerobic	Cr monohydrate	20 - 4 - 7	0	140	Bicycle ergometer	VO <sub>2</sub> peak
Reardon et al. (2006)	Australia	13	70	19–22	Recreation	Aerobic	Cr monohydrate	20 - 4 - 7	5 - 1 - 21	168	Bicycle ergometer	VO <sub>2</sub> peak
Smith et al. (2011)	USA	55	49	21.7	Recreation	Aerobic	di-Cr citrate	20 - 4 - 5	0	100	Treadmill	VO <sub>2</sub> max
Sterkowicz et al. (2012)	Poland	10	100	21.2	Competition (judoists)	Aerobic	Cr malate	0	5 - 1 - 42	210	Treadmill	VO <sub>2</sub> peak
Van Loon et al. (2003)	Netherlands	20	100	20.6	Sedentary	None	Cr monohydrate	20 - 4 - 5	2	174	Bicycle ergometer	VO <sub>2</sub> peak
Villanueva, He, and Schroeder (2014)	USA	14	100	68.1	Recreation	Anaerobic (strength)	Cr monohydrate	24 – 3 – 5	5,5-1 - 79	552	Bicycle ergometer	VO <sub>2</sub> peak
Note: Age: mean or inter	rval; FTP, fitness	training p	rogram; HIIT, h	igh intensit	y interval trair	ing; NA, not availa	ble; MTP, military trai	ning program.				

Table 1. Characteristics of included studies.

CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION 😔 5

studies assessed body mass changes (Balsom et al. 1993; Canete et al. 2006; Eijnde et al. 2003; Forbes et al. 2017; Graef et al. 2009; Hickner et al. 2010; Kresta et al. 2014; Lawrence et al. 1997; Murphy et al. 2005; Reardon et al. 2006; Smith et al. 2011; Van Loon et al. 2003).

#### Aerobic outcomes: VO<sub>2</sub>max and other parameters

Measurements of maximal oxygen consumption were reported in VO<sub>2</sub>max (Balsom et al. 1993; Murphy et al. 2005; Hickner et al. 2010; Smith et al. 2011; Kuethe et al. 2006; Van Loon et al. 2003; Lázaro da Silveira et al. 2014; Villanueva, He, and Schroeder 2014) or VO<sub>2</sub>peak (Nelson et al. 2000; Canete et al. 2006; Carvalho et al. 2012; Reardon et al. 2006; Eijnde et al. 2003; Sterkowicz et al. 2012; Forbes et al. 2017; Graef et al. 2009; Kresta et al. 2014; Barnett, Hinds, and Jenkins 1996; Lawrence et al. 1997). We used VO<sub>2</sub>max as a generalization in this study. Nine studies measured VO2max in L/min (Nelson et al. 2000; Murphy et al. 2005; Hickner et al. 2010; Van Loon et al. 2003; Eijnde et al. 2003; Forbes et al. 2017; Graef et al. 2009; Barnett, Hinds, and Jenkins 1996; Lawrence et al. 1997) and eleven in mL/kg/min (Balsom et al. 1993; Canete et al. 2006; Carvalho et al. 2012; Smith et al. 2011; Reardon et al. 2006; Kuethe et al. 2006; Sterkowicz et al. 2012; Lázaro da Silveira et al. 2014; Forbes et al. 2017; Kresta et al. 2014; Villanueva, He, and Schroeder 2014). Among them, one study reported both L/min and mL/kg/ min (Forbes et al. 2017). Most studies measured VO<sub>2</sub>max with gas exchange analysis during incremental exercise tests such as the bicycle ergometer test (Barnett, Hinds, and Jenkins 1996; Forbes et al. 2017; Graef et al. 2009; Hickner et al. 2010; Kresta et al. 2014; Murphy et al. 2005; Nelson et al. 2000; Reardon et al. 2006; Van Loon et al. 2003; Eijnde et al. 2003; Canete et al. 2006; Carvalho et al. 2012), treadmill test (Balsom et al. 1993; Smith et al. 2011; Sterkowicz et al. 2012; Kuethe et al. 2006; Villanueva, He, and Schroeder 2014), or rowing ergometer test (Lawrence et al. 1997). The incremental tests were as close as possible to the training habitus of participants. VO2max was also extrapolated from sub-maximal measures of VO<sub>2</sub>max in two studies (Ebbeling et al. 1991; Villanueva, He, and Schroeder 2014) and estimated through a 12-minute Cooper test in one study (Lázaro da Silveira et al. 2014). Ten studies also assessed ventilatory threshold, using the V-slope method (Beaver, Wasserman, and Whipp 1986) in six studies (Forbes et al. 2017; Graef et al. 2009; Nelson et al. 2000; Kuethe et al. 2006; Bert O. Eijnde et al. 2003; Carvalho et al. 2012) - that is, the point where VCO<sub>2</sub> production increases more than VO<sub>2</sub> consumption -, the "Wasserman" method (Wasserman et al. 1973) in three studies (Canete et al. 2006; Kresta et al. 2014; Smith et al. 2011) - that is, the point where VE/VO<sub>2</sub> increases without a concomitant increase in VE/VCO<sub>2</sub>, and without further information in one study (Sterkowicz et al. 2012). Six studies reported time to exhaustion (Smith et al. 2011; Graef et al. 2009; Kresta et al. 2014; Murphy et al. 2005) or maximal power output (Van Loon et al. 2003; Eijnde et al. 2003; Canete et al. 2006) at the incremental tests (Table 1 and Appendix S3).

#### **Creatine supplementation**

Cr monohydrate was used in 74% of studies, Cr citrate in two studies (Graef et al. 2009; Smith et al. 2011), Cr malate in one study (Sterkowicz et al. 2012), and not reported in two studies (Carvalho et al. 2012; Kuethe et al. 2006). A loading dose was used in twelve studies, that is, a dose  $\geq$ 20 g/day or 0.3 g/kg, which had shown the greatest effectiveness for increasing muscle total Cr content with minimal Cr losses through renal excretion (Harris, Söderlund, and Hultman 1992), split in two (Forbes et al. 2017), three (Canete et al. 2006; Lázaro da Silveira et al. 2014; Villanueva, He, and Schroeder 2014) or four (Nelson et al. 2000; Murphy et al. 2005; Smith et al. 2011; Reardon et al. 2006; Kuethe et al. 2006; Van Loon et al. 2003; Kresta et al. 2014; Lawrence et al. 1997) intakes per day, during 4-7 days for all studies except one that used a loading dose for a prolonged period (Kuethe et al. 2006). A maintenance dose ranging from 2 (Murphy et al. 2005) to 10 g/day (Murphy et al. 2005) was used in six studies, once-daily except for one study (Murphy et al. 2005). Seven studies did not use a loading dose and supplemented only with a low dose of Cr (Balsom et al. 1993; Hickner et al. 2010; Carvalho et al. 2012; Eijnde et al. 2003; Sterkowicz et al. 2012; Graef et al. 2009; Barnett, Hinds, and Jenkins 1996). In total, the CS was 285g on average, ranging from 42g (Barnett, Hinds, and Jenkins 1996) to 912g (Eijnde et al. 2003), over 42 days, ranging from four days (Barnett, Hinds, and Jenkins 1996) to six months (Eijnde et al. 2003) (Table 1).

#### Training during supplementation

All participants performed the same physical training in all studies and differed only by supplementation (Cr or placebo). A standardized training program was proposed in six studies: high-intensity interval training (HIIT) (Graef et al. 2009; Forbes et al. 2017), resistance (Villanueva, He, and Schroeder 2014), aerobic (Reardon et al. 2006), or mixed training (Eijnde et al. 2003; Lázaro da Silveira et al. 2014). Nine studies maintained the usual physical activity of participants, i.e., running (Balsom et al. 1993), cycling (Hickner et al. 2010), rowing (Lawrence et al. 1997), team sports (Murphy et al. 2005), judo (Sterkowicz et al. 2012) or other recreational activities (Nelson et al. 2000; Smith et al. 2011; Kresta et al. 2014; Barnett, Hinds, and Jenkins 1996). Four studies included sedentary participants without exercise intervention (Van Loon et al. 2003; Canete et al. 2006; Kuethe et al. 2006; Carvalho et al. 2012). We classified exercise training as "aerobic" (68.9%), "anaerobic" (11.8%) or "none" (19.3%) (Table 1).

#### Meta-analysis

Considering all measures of VO<sub>2</sub>max, there were no differences in any outcomes at baseline between-group CS and placebo groups (Appendix S4). Using changes from baseline to after the supplementation, VO<sub>2</sub>max increased less in the CS group than the control group (ES = -0.30, 95%CI = -0.50 to -0.11, p=0.003). Stratification showed a lower increase in the CS group for VO<sub>2</sub>max in L/min (ES= -0.39, 95%CI = -0.67 to -0.12, p=0.005), and for cycling (ES= -0.33, 95%CI = -0.58to -0.09, p=0.007). Other aerobic outcomes (ventilatory threshold, time to exhaustion, maximal power output) did not differ between groups (Figure 3). Considering all measures of VO<sub>2</sub>max and only VO<sub>2</sub>max expressed in L/min for the single study that reported both units (Forbes et al. 2017), sensitivity analyses showed similar findings, that is, a lower increase in VO2max in the CS compared with the control group (ES = -0.32, 95%CI = -0.52 to -0.11, p = 0.002) (Appendix S3). Results were nearly identical with VO<sub>2</sub>max expressed in mL/kg/min.

#### Other sensitivity analyses

Meta-analyses comparing VO<sub>2</sub>max after CS between groups demonstrated similar results than meta-analyses on changes, that is, a significant lower VO<sub>2</sub>max in the CS

compared with the placebo group (ES= -0.20, 95%CI = -0.39 to -0.001, p = 0.049), as well as for VO<sub>2</sub>max expressed in L/min (ES= -0.32, 95%CI = -0.59 to -0.04, p = 0.022), and a tendency for cycling (ES= -0.22, 95%CI = -0.46 to 0.02, p = 0.074) (Appendix S4). We also computed meta-analyses on VO<sub>2</sub>max changes within groups showing that VO<sub>2</sub>max increased in the placebo group (ES= 0.35, 95%CI = 0.15-0.54, p = 0.001), with only a tendency within the CS group (ES= 0.18, 95%CI = -0.01 to 0.37, p = 0.060). Despite a very limited number of studies (n = 3) for this parameter, maximal power output increased in the CS group (ES= 0.45, 95%CI = 0.03-0.88, p = 0.038). All aforementioned meta-analyses were repeated after excluding studies not evenly distributed around the base of the meta-funnel (Figure 4), and demonstrated similar findings (Appendix S5). Lastly, we also repeated all meta-analyses in the subgroup of young and healthy participants, and results were similar, that is, a lower VO<sub>2</sub>max increase in the CS compared to the placebo group using

	n studies	I-squared			Effect size (95CI)	Weight (%)
All				1		
VO2 max						
by unit of measure						
mL/kg/min	11 (12)	0.0	<b></b> _	<b></b>	-0.18 (-0.45 to 0.09)	100.0
L/min	9 (9)	0.0			-0.39 (-0.67 to -0.12)	100.0
by training						
Running	6 (7)	27.0	O	<b></b>	-0.27 (-0.69 to 0.15)	30.3
Cycling	12 (12)	0.0			-0.33 (-0.58 to -0.09)	64.7
Rowing	1 (1)	0.0			-0.10 (-0.98 to 0.78)	5.0
Overall	19 (20)	0.0	<b>_</b>		-0.30 (-0.50 to -0.11)	100.0
Other parameters						
Maximal power	3 (3)	66.6			-0.10 (-1.01 to 0.81)	100.0
Time to exhaustion	4 (5)	17.2			-0.12 (-0.52 to 0.28)	100.0
Ventilatory threshold	10 (11)	80.8			0.21 (-0.38 to 0.79)	100.0
After exclusion from	m metafun	nel				
VO2 max						
by unit of measure						
mL/kg/min	10 (11)	5.3	<b></b> _		-0.07 (-0.34 to 0.21)	100.0
L/min	9 (9)	0.0	O		-0.39 (-0.67 to -0.12)	100.0
by training						
Running	5 (6)	26.4			-0.07 (-0.44 to 0.30)	29.3
Cycling	12 (12)	0.0			-0.32 (-0.55 to -0.08)	65.7
Rowing	1 (1)	0.0	<u>_</u>		-0.10 (-0.98 to 0.78)	5.0
Overall	18 (19)	0.0	<b></b>		-0.25 (-0.45 to -0.05)	100.0
Other parameters	. ,				, ,	
Maximal power	3 (3)	62.3			-0.10 (-1.01 to 0.81)	100.0
Time to exhaustion	4 (5)	0.0			-0.12 (-0.52 to 0.28)	100.0
Ventilatory threshold	7 (8)	65.1		0	0.28 (-0.18 to 0.74)	100.0
Only young and he	althy					
VO2 max						
by unit of measure						
mL/kg/min	7 (8)	23.4	O	<u> </u>	-0.24 (-0.62 to 0.15)	100.0
L/min	8 (8)	0.0			-0.30 (-0.61 to 0.01)	100.0
by training					,	
Running	4 (5)	47.9			-0.26 (-0.83 to 0.31)	33.6
Cycling	9 (9)	0.0			-0.34 (-0.64 to -0.04)	59.4
Rowing	1 (1)	0.0	O		-0.10 (-0.98 to 0.78)	7.0
Overall	14 (15)	0.0	<b>—</b>		-0.29 (-0.53 to -0.06)	100.0
Other parameters	. ,				, ,	
Maximal power	1 (1)	0.0			-0.99 (-2.13 to 0.15)	100.0
Time to exhaustion	4 (5)	17.2			-0.12 (-0.52 to 0.28)	100.0
Ventilatory threshold	6 (7)	42.2			0.66 (0.23 to 1.10)	100.0
· · ·			-0.8 -0.3	0.2 0.7		



#### VO<sub>2</sub>max changes stratified by training



#### **Aerobic changes**



Figure 4. Funnel plots of aerobic changes after supplementation period between groups.

changes between groups (ES= -0.26, 95%CI = -0.49 to -0.02, p = 0.031), a lower VO<sub>2</sub>max after CS in the CS compared to the placebo group (ES = -0.26, -95%CI = 0.49 to -0.02, p = 0.031), an increase in VO<sub>2</sub>max within the placebo group (ES = 0.25, 95% CI = 0.02-0.48, p = 0.035) and not within the CS group (ES = 0.10, 95% CI = -0.13 to 0.32, p = 0.41). Using changes between groups, the ventilatory threshold increased in the CS compared to the control group (ES = 0.66, 95%CI = 0.23-1.1, p = 0.003) (Figure 3 and Appendix S6).

#### **Meta-regressions**

The meta-regressions failed to show any influencing variables on the VO<sub>2</sub>max, that is, the putative influence of individuals, supplementation, or training characteristics. The adverse effect of CS on VO<sub>2</sub>max was not linked to body mass or changes in body mass, which did not significantly vary in both groups. The limited number of patients with heart failure precluded analyses on the influence of health status on VO<sub>2</sub>max (Figure 5).

	Effect size (95CI)	p- value
Changes between groups		rarao
Performance at T0	0.008 (-0.01 to 0.02)	0.122
Population		
Age (per ten-year) –	-0.03 (-0.15 to 0.08)	0.572
Sex (per ten-percent male)	-0.02 (-0.08 to 0.03)	0.351
Physical activity at baseline:		
competition vs recreation	0.23 (-0.47 to 0.93)	0.494
competition vs sedentary	- 0.37 (-0.38 to 1.13)	0.309
recreation vs sedentary	0.14 (-0.34 to 0.63)	0.544
Supplementation	insufficient data	
Loading dose (posology per 20-gr)	0.01 (-0.43 to 0.46)	0.923
Loading dose (duration per 7-day)	-0.06 (-0.27 to 0.14)	0.514
Maintenance dose (posology per 1-gr)	-0.02 (-0.08 to 0.04)	0.563
Total dose (per 100-gr)	-0.02 (-0.10 to 0.04)	0.387
Total duration (per 30-day)	-0.03 (-0.13 to 0.07)	0.547
Training during supplementation:		
aerobic vs anaerobic	-0.18 (-0.78 to 0.42)	0.534
aerobic vs none	-0.11 (-0.64 to 0.41)	0.656
T1 erect vs T1 control	0.07 (-0.63 to 0.76)	0.841
Performance at T0	0.006 (-0.01 to 0.02)	0.218
Population	0.000 (-0.01 10 0.02)	0.210
Age (per ten-vear)	0.05 (-0.07 to 0.16)	0.407
Sex (per ten-percent male)	-0.03 (-0.08 to 0.03)	0.304
Physical activity at baseline:		
competition vs recreation	-0.03 (-0.66 to 0.59)	0.896
competition vs sedentary	0.04 (-0.65 to 0.73)	0.896
recreation vs sedentary	0.08 (-0.42 to 0.55)	0.789
Health condition (Healthy as reference)	insufficient data	
Supplementation	0.00 ( 0.40 to 0.40)	0.040
Loading dose (posology per 20-gr)	- 0.02 (-0.40 to 0.40)	0.916
Maintenance dose (nosology per 1-gr)	-0.03 (-0.21 to 0.14)	0.700
Total dose (per 100-gr)	-0.01 (-0.08 to 0.05)	0.664
Total duration (per 30-day)	-0.02 (-0.12 to 0.07)	0.648
Training during supplementation:		
aerobic vs anaerobic	-0.26 (-0.86 to 0.33)	0.361
aerobic vs none	-0.19 (-0.72 to 0.33)	0.446
anaerobic vs none	0.07 (-0.63 to 0.77)	0.833
T1 creatine vs T0 creatine		
Performance at 10	0.001 (-0.01 to 0.01)	0.767
Age (per ten year)	0.07 (0.04 to 0.20)	0 204
Sex (per ten-percent male)	0.07 (-0.04 to 0.20)	0.204
Physical activity at baseline:	0.01 (-0.04 10 0.00)	0.011
competition vs recreation	0.11 (-0.49 to 0.71)	0.711
competition vs sedentary	-0.02 (-0.67 to 0.63)	0.944
recreation vs sedentary	-0.13 (-0.59 to 0.33)	0.563
Health condition (Healthy as reference)	insufficient data	
Supplementation		
Loading dose (posology per 20-gr)	- 0.02 (-0.40 to 0.40)	
Loading dose (duration per /-day)	0.03 (-0.22 to 0.17)	0.784
Total dose (per 100 gr)	0.03 (-0.03 to 0.09)	0.264
Total duration (per 30-day)	0.09 (-0.003 to 0.19)	0.056
Training during supplementation:		
aerobic vs anaerobic	-0.46 (-1.06 to 0.14)	0.127
aerobic vs none	0.006 (-0.48 to 0.49)	0.981
anaerobic vs none	0.46 (-0.22 to 1.14)	0.170
T1 control vs T0 control		
Performance at T0	-0.004 (-0.01 to 0.01)	0.403
Population		
Age (per ten-year)	0.01 (-0.02 to 0.02)	0.087
Dhysical activity at baseline:	0.02 (-0.04 10 0.07)	0.475
competition vs recreation	-0.28 (-0.98 to 0.42)	0 4 1 4
competition vs sedentary	-0.48 (-1.24 to 0.27)	0.192
recreation vs sedentary	-0.21 (-0.69 to 0.28)	0.381
Health condition (Healthy as reference)	insufficient data	
Supplementation		
Loading dose (posology per 20-gr)	-0.26 (-0.70 to 0.19)	0.239
Loading dose (duration per 7-day)	0.005 (-0.21 to 0.20)	0.956
Maintenance dose (posology per 1-gr)	0.03 (-0.03 to 0.09)	0.007
Total dose (per 100-gr)	0.08 (0.009 to 0.15)	0.029
Training during supplementation:	0.10 (0.001 to 0.20)	0.047
aerobic vs anaerobic	-0.52 (-1.14 to 0.00)	0 000
aerobic vs none	-0.05 (-0.57 to 0.48)	0.856
anaerobic vs none	0.48 (-0.23 to 1.19)	0.173

Figure 5. Meta-regressions for the main outcome (VO<sub>2</sub>max).

-1

#### Discussion

The main findings were that CS is detrimental to  $VO_2max$ , especially for cycling. If CS was also not beneficial on the maximal aerobic parameters associated with  $VO_2max$ , the ventilatory threshold seemed to be improved. Results were independent of sociodemographic or supplementation characteristics.

Cr is well-known for its ergogenic effects in acute high-intensity exercises. However, current results of our

meta-analysis led to adverse effects of CS on endurance capacity assessed with VO<sub>2</sub>max, which increased in the placebo but not in the CS group. VO<sub>2</sub>max limiting factors are shared between central factors for ~70% and peripheral factors for ~30% (di Prampero and Ferretti 1990). Thus, O<sub>2</sub> delivery and particularly maximal cardiac output are the primary limiting factors of VO<sub>2</sub>max during exercise (Bassett 2000). Cr is known to induce water retention in tissues such as skeletal muscle (Casey et al. 1996) and, potentially, cardiomyocytes (Ipsiroglu et al. 2001). However, its cardiomyocytes' effects on contractile function and blood flow during exercise are lacking and still questionable. In addition to the cardiac function, O<sub>2</sub> delivery to working muscles also depends on arterial oxygen content. Even if hemoglobin levels are not modified following CS (Preen et al. 2001; Hickner et al. 2010; Robinson et al. 2000), CS can alter plasma volume during exercise (Hickner et al. 2010) effects on muscle oxygen supply and VO<sub>2</sub>max were not fully demonstrated. Finally, the effects of CS on central limiting factors of VO<sub>2</sub>max do not appear to be essential. This can be explained by the fact that CS rather acts at the peripheral muscle level. Since CS is well-known to improve anaerobic performance through muscle hypertrophy and the higher recruitment in fast-twitch muscle fibers (Casey et al. 1996), changes in skeletal muscle energy metabolism could have explained our negative findings on VO2max. This hypothesis is supported by the lack of improvement in muscle oxidative capacity following CS (Van Loon et al. 2003; Thompson et al. 1996). The negative effect of CS on VO<sub>2</sub>max should be considered, especially in endurance athletes for whom VO<sub>2</sub>max is a determining factor of performance.

The ventilatory threshold refers to the point during exercise at which ventilation starts to increase at a faster rate than VO<sub>2</sub> related to the onset of lactate accumulation (Wasserman et al. 1973). The ventilatory threshold occurs at a higher percentage of VO<sub>2</sub>max in well-trained endurance athletes (Ivy et al. 1980) and can predict endurance performance, regardless of the level of training (Bassett 2000; Reybrouck et al. 1986). The increase in the ventilatory threshold found after CS in the young and healthy follows greater exercise efficiency at submaximal workloads, resulting in decreased O<sub>2</sub> consumption (Nelson et al. 2000; Murphy et al. 2005; Hickner et al. 2010). Hypotheses are that CrP hydrolysis consumes hydrogen ions and might contribute to the buffering of intracellular acidosis when ATP resynthesis occurs from CrP stores (Mesa et al. 2002). Moreover, increased muscle CrP levels due to CS could delay the decrease in the ATP/ADP ratio needed to stimulate mitochondrial respiration and VO<sub>2</sub> (Nelson et al. 2000). An increase in mechanical efficiency could also participate (Nelson et al. 2000; Da Silva Azevedo et al. 2019). Mitochondrial changes following CS at a cellular level are yet to be explored. The effects of age in ventilatory threshold improvement remain unclear (Thomas et al. 1985). Despite being poorly studied, maximal aerobic power output did not change following CS in our meta-analysis (Canete et al. 2006; Van Loon et al. 2003; Eijnde et al. 2003), in coherence with the fact that CS rather acts on fast-twitch muscle fibers (Hill and Rowell 1996). There was no change in time to exhaustion, but an incremental exercise test targets to reach  $VO_2max$  in a limited time, and therefore this parameter is mainly dependent on the incremental protocol.

We showed that CS limited more VO<sub>2</sub>max in cycling than in running or rowing, but it may be biased considering the greatest number of participants performing cycling. While HIIT partly involves anaerobic capacities and shows interesting results on VO<sub>2</sub>max in the literature (Tabata et al. 1996), the lack of data for HIIT in our meta-analyses did not permit to retrieval of an influence of HIIT on VO<sub>2</sub>max when associated with CS (Forbes et al. 2017; Graef et al. 2009). We also failed to demonstrate any relationships between volume and intensity of training on the negative effects of CS on VO2max, despite abundant dose-response literature in anaerobic performance (Lanhers et al. 2015 and 2017). Regarding characteristics of supplementation, Cr monohydrate was mainly used, precluding further comparisons between Cr forms. Improvement in VO<sub>2</sub>max is altered with CS regardless of the doses. We failed to demonstrate a dose-response relationship, even though CS varied from 4 days to 6 months. Even if optimal doses to increase muscle total Cr content with minimal renal Cr losses (Harris, Söderlund, and Hultman 1992), favoring anaerobic performances, mitochondrial changes following CS at a cellular level are yet to be explored. CS has been most extensively studied in young and trained males.

Interestingly, some studies also explored the putative benefits of CS in specific populations, such as in the elderly and patients with heart failure. In those populations, CS did not improve VO<sub>2</sub>max, regardless of the type of physical activity (Canete et al. 2006; Eijnde et al. 2003; Villanueva, He, and Schroeder 2014), which seem coherent because the central limitation appears even more predominant than in young athletes. However, it should be noted that CS is known to benefit the elderly, such as improving muscular strength and functional performance (Kuethe et al. 2006) (Devries and Phillips 2014). Lastly, even if strength gains were reported to be greater in males (McNaughton, et al. 1998; Tyka et al. 2015), we did not find sex-based differences on VO<sub>2</sub>max changes with CS, following one study that included gender comparisons (Smith et al. 2011).

This is the first meta-analysis that has focused on the effect of CS on VO<sub>2</sub>max. Many studies did not report and included all their results in the meta-analysis. For instance, studies reported baseline measurement without measurement after supplementation for VO<sub>2</sub>max or without its change expression (Nelson et al. 2000; McNaughton, Dalton, and Tarr 1998) or did not express dispersion of its measurement (Tyka et al. 2015). Our study has some limitations inherited from all meta-analyses (LeLorier et al. 1997), but the use of rigorous inclusion criteria, that is, double-blind RCTs limited the publication bias. Reporting bias due to the scarcity of publications with negative findings is common to all systematic reviews and meta-analyses. However, it could have reinforced our main findings. A publication bias was also assessed according to funnel plots, and sensitivity analyses showed similar results on the main outcome. Measurements of VO2max varied among studies, which could have led to a measurement bias. The rigorous determination of VO<sub>2</sub>max depends on different criteria (plateau in oxygen consumption, respiratory exchange ratio > 1,1, heart rate greater than age-predicted maximal heart rate, blood lactates > 6-8 mmol or physical exhaustion (Lacour and Flandrois 1977)). In our meta-analysis, VO<sub>2</sub>max was reported through rigorous determination by three studies (Hickner et al. 2010; Murphy et al. 2005; Smith et al. 2011). Four studies (Nelson et al. 2000; Canete et al. 2006; Forbes et al. 2017; Graef et al. 2009) assessed VO2peak as the highest average VO<sub>2</sub> obtained for any period of time between 15-sec (Graef et al. 2009) and 1-min (Canete et al. 2006) without specifying if a VO<sub>2</sub>plateau was obtained. Ten studies did not provide additional information for the determination of the maximum oxygen uptake and mentioned VO<sub>2</sub>max (Balsom et al. 1993; Van Loon et al. 2003) or VO<sub>2</sub>peak (Carvalho et al. 2012; Reardon et al. 2006; Kuethe et al. 2006; Eijnde et al. 2003; Sterkowicz et al. 2012; Kresta et al. 2014; Barnett, Hinds, and Jenkins 1996; Lawrence et al. 1997) without precision, and two studies estimated VO<sub>2</sub>max (Lázaro da Silveira et al. 2014; Villanueva, He, and Schroeder 2014). To assess the impact of training associated with CS, we used a classification that may have generated a bias. Most of the performance variables included in this meta-analysis were measured in a laboratory setting, and field-based endurance performance also must be assessed.

#### **Conclusion and practical implications**

Our analysis showed the negative effects of CS on  $VO_2max$ , regardless of the supplementation protocols, physical training, and population characteristics. Considering that creatine is the most widely used dietary supplement in sport, particular attention toward its use should be paid to endurance athletes.

#### **Author contributions**

Conceived and designed the study: FD and JBBM. Conducted the systematic literature search: DG, CL. Final approval of eligible articles: all authors. Analyzed the data: DG, FD and BP. Wrote the first draft of the article: DG, FD, UU. Critical revision of the article: all authors. Integrity of the data analysis: DG, FD.

#### Acknowledgements

The authors received no specific funding for this work.

#### **Disclosure statement**

The authors declare no conflict of interest.

#### Funding

This work received no specific external funding.

#### ORCID

Charlotte Lanhers D http://orcid.org/0000-0002-6584-8411 Reza Bagheri D http://orcid.org/0000-0003-1433-2906 Ukadike Chris Ugbolue D http://orcid.org/0000-0002-6640-4126 Emmanuel Coudeyre D http://orcid.org/0000-0001-5753-2890 Bruno Pereira D http://orcid.org/0000-0003-3778-7161 Marek Zak D http://orcid.org/0000-0003-0881-9232 Jean-Baptiste Bouillon-Minois D http://orcid. org/0000-0002-6556-4187 Frédéric Dutheil D http://orcid.org/0000-0002-1468-6029

#### Data availability statement

All relevant data are within the paper.

#### References

- Balsom, P. D., S. D. Harridge, K. Söderlund, B. Sjödin, and B. Ekblom. 1993. Creatine supplementation per se does not enhance endurance exercise performance. *Acta Physiologica Scandinavica* 149 (4):521–3. doi: 10.1111/j.1748-1716.1993.tb09649.x.
- Barnett, C., M. Hinds, and D. G. Jenkins. 1996. Effects of oral creatine supplementation on multiple sprint cycle performance. Australian Journal of Science and Medicine in Sport 28 (1):35–9.
- Bassett, D. R. 2000. Limiting factors for maximum oxygen uptake and determinants of endurance performance. *Medicine & Science in Sports* & *Exercise* 32 (1):70–84. doi: 10.1097/00005768-200001000-00012.
- Beaver, W. L., K. Wasserman, and B. J. Whipp. 1986. A new method for detecting anaerobic threshold by gas exchange. *Journal of Applied Physiology (Bethesda, Md.: 1985)* 60 (6):2020–7. doi: 10.1152/jappl.1986.60.6.2020.
- Borenstein, M., L. V. Hedges, J. P. T. Higgins, and H. R. Rothstein. 2009. Introduction to meta-analysis. United Kingdom: Wiley, Ltd. doi: 10.9780470743386.
- Canete, S., C. P. Earnest, S. J. Fleck, and A. Lucia. 2006. Does creatine supplementation improve functional capacity in elderly women? *The Journal of Strength & Conditioning Research* 20 (1):22.
- Carvalho, A. P. P. F., S. Rassi, K. E. Fontana, K. d S. Correa, and R. H. F. Feitosa. 2012. Influence of creatine supplementation on the functional capacity of patients with heart failure. *Arquivos Brasileiros de Cardiologia* 99 (1):623-9. doi: 10.1590/ s0066-782x2012005000056.
- Casey, A., D. Constantin-Teodosiu, S. Howell, E. Hultman, and P. L. Greenhaff. 1996. Creatine ingestion favorably affects performance and muscle metabolism during maximal exercise in humans. *The American Journal of Physiology* 271 (1Pt 1):E31–37. doi: 10.1152/ ajpendo.1996.271.1.E31.
- Chidnok, W., F. J. DiMenna, S. J. Bailey, M. Burnley, D. P. Wilkerson, A. Vanhatalo, and A. M. Jones. 2013. .VO2max is not altered by self-pacing during incremental exercise . *European Journal of Applied Physiology* 113 (2):529–39. doi: 10.1007/s00421-012-2478-6.
- Cohen, J. 1988. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, N.J.: L. Erlbaum Associates.
- Da Silva Azevedo, A. P., F. Michelone Acquesta, A. H. Lancha, Jr., R. Bertuzzi, J. R. Poortmans, A. C. Amadio, and J. Cerca Serrão. 2019. Creatine supplementation can improve impact control in high-intensity interval training. *Nutrition (Burbank, Los Angeles County, Calif.)* 61:99–104. doi: 10.1016/j.nut.2018.09.020.
- Dawson, B., M. Cutler, A. Moody, S. Lawrence, C. Goodman, and N. Randall. 1995. Effects of oral creatine loading on single and repeated maximal short sprints. *Australian Journal of Science and Medicine* in Sport 27 (3):56–61.
- DerSimonian, R., and N. Laird. 1986. Meta-analysis in clinical trials. Controlled Clinical Trials 7 (3):177–88. doi: 10.1016/0197-2456(86)90046-2.
- Devries, M. C., and S. M. Phillips. 2014. Creatine supplementation during resistance training in older adults—A meta-analysis. *Medicine* & Science in Sports & Exercise 46 (6):1194–203. doi: 10.1249/ MSS.00000000000220.
- di Prampero, P. E., and G. Ferretti. 1990. Factors limiting maximal oxygen consumption in humans. *Respiration Physiology* 80 (2-3):113– 28. doi: 10.1016/0034-5687(90)90075-A.

- Ebbeling, C. B., A. Ward, E. M. Puleo, J. Widrick, and J. M. Rippe. 1991. Development of a single-stage submaximal treadmill walking test. *Medicine and Science in Sports and Exercise* 23 (8):966–73.
- Eijnde, B. O., M. Van Leemputte, M. Goris, V. Labarque, Y. Taes, P. Verbessem, L. Vanhees, M. Ramaekers, B. Vanden Eynde, R. Van Schuylenbergh, et al. 2003. Effects of creatine supplementation and exercise training on fitness in men 55–75 Yr old. *Journal of Applied Physiology* 95 (2):818–28. doi: 10.1152/japplphysiol.00891.2002.
- Eijnde, B. O. ', B. Urso, E. A. Richter, P. L. Greenhaff, and P. Hespel. 2001. Effect of oral creatine supplementation on human muscle GLUT4 protein content after immobilization. *Diabetes* 50 (1) American Diabetes Association: :18–23. doi: 10.2337/diabetes.50.1.18.
- Engelhardt, M., G. Neumann, A. Berbalk, and I. Reuter. 1998. Creatine supplementation in endurance sports. *Medicine and Science in Sports* and Exercise 30 (7):1123–9. doi: 10.1097/00005768-199807000-00016.
- Forbes, S. C., N. Sletten, C. Durrer, É. Myette-Côté, D. Candow, and J. P. Little. 2017. Creatine monohydrate supplementation does not augment fitness, performance, or body composition adaptations in response to four weeks of high-intensity interval training in young females. International Journal of Sport Nutrition and Exercise Metabolism 27 (3):285–92. doi: 10.1123/ijsnem.2016-0129.
- Gastin, P. B. 2001. Energy system interaction and relative contribution during maximal exercise. Sports Medicine (Auckland, N.Z.) 31 (10):725-41. doi: 10.2165/00007256-200131100-00003.
- Graef, J. L., A. E. Smith, K. L. Kendall, D. H. Fukuda, J. R. Moon, T. W. Beck, J. T. Cramer, and J. R. Stout. 2009. The effects of four weeks of creatine supplementation and high-intensity interval training on cardiorespiratory fitness: A randomized controlled trial. *Journal of the International Society of Sports Nutrition* 6 (1):18. doi: 10.1186/1550-2783-6-18.
- Harris, R. C., K. Söderlund, and E. Hultman. 1992. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. *Clinical Science (London)* 83 (3):367–74. doi: 10.1042/cs0830367.
- Hawkins, M. N., P. B. Raven, P. G. Snell, J. Stray-Gundersen, and B. D. Levine. 2007. Maximal oxygen uptake as a parametric measure of cardiorespiratory capacity. *Medicine and Science in Sports and Exercise* 39 (1):103–7. doi: 10.1249/01.mss.0000241641.75101.64.
- Hickner, R. C., J. David, J. Dyck, H. Sklar, and P. Hatley. 2010. Effect of 28 days of creatine ingestion on muscle metabolism and performance of a simulated cycling road race 13.
- Hill, A. V., and H. Lupton. 1923. Muscular exercise, lactic acid, and the supply and utilization of oxygen. QIM os-16 (62):135–71. doi: 10.1093/qjmed/os-16.62.135.
- Hill, D. W., and A. L. Rowell. 1996. Running velocity at VO2 max. Medicine and Science in Sports and Exercise 28 (1):114-9. doi: 10.1097/00005768-199601000-00022.
- Ipsiroglu, O. S., C. Stromberger, J. Ilas, H. Höger, A. Mühl, and S. Stöckler-Ipsiroglu. 2001. Changes of tissue creatine concentrations upon oral supplementation of creatine-monohydrate in various animal species. *Life Sciences* 69 (15):1805–15. doi: 10.1016/ S0024-3205(01)01268-1.
- Ivy, J. L., R. T. Withers, P. J. Van Handel, D. H. Elger, and D. L. Costill. 1980. Muscle respiratory capacity and fiber type as determinants of the lactate threshold. *Journal of Applied Physiology: respiratory, Environmental and Exercise Physiology* 48 (3):523–7. doi: 10.1152/jappl.1980.48.3.523.
- Ju, J.-S., J. L. Smith, P. J. Oppelt, and J. S. Fisher. 2005. Creatine feeding increases GLUT4 expression in rat skeletal muscle. American Journal of Physiology-Endocrinology and Metabolism 288 (2):E347– 352. doi: 10.1152/ajpendo.00238.2004.
- Kipp, S., R. Kram, and W. Hoogkamer. 2019. Extrapolating metabolic savings in running: Implications for performance predictions. *Frontiers in Physiology* 10:79(February): 79. doi: 10.3389/ fphys.2019.00079.
- Kreider, R. B., and J. R. Stout. 2021. Creatine in health and disease. *Nutrients* 13 (2):447. doi: 10.3390/nu13020:447.
- Kresta, J. Y., J. M. Oliver, A. R. Jagim, J. Fluckey, S. Riechman, K. Kelly, C. Meininger, S. U. Mertens-Talcott, C. Rasmussen, and R. B. Kreider. 2014. Effects of 28 days of beta-alanine and creatine supplementation

on muscle carnosine, body composition and exercise performance in recreationally active females. *Journal of the International Society of Sports Nutrition* 11 (1):55. doi: 10.1186/s12970-014-0055-6.

- Kuethe, F., A. Krack, B. M. Richartz, and H. R. Figulla. 2006. Creatine supplementation improves muscle strength in patients with congestive heart failure. *Pharmazie* 61 (3):218.
- Lacour, J. R., and R. Flandrois. 1977. Role of aerobic metabolism in prolonged intensive exercise. Journal de Physiologie 73 (2):89–130.
- Lanferdini, F. J., E. S. Silva, E. Machado, G. Fischer, and L. A. Peyré-Tartaruga. 2020. Physiological predictors of maximal incremental running performance. *Frontiers in Physiology* 11:979. doi: 10.3389/fphys.2020.00979.
- Lanhers, C., B. Pereira, G. Naughton, M. Trousselard, F.-X. Lesage, and F. Dutheil. 2015. Creatine supplementation and lower limb strength performance: A systematic review and meta-analyses. *Sports Medicine* 45 (9):1285–94. doi: 10.1007/s40279-015-0337-4.
- Lanhers, C., B. Pereira, G. Naughton, M. Trousselard, F.-X. Lesage, and F. Dutheil. 2017. Creatine supplementation and upper limb strength performance: A systematic review and meta-analysis. *Sports Medicine* 47 (1):163–73. doi: 10.1007/s40279-016-0571-4.
- Lawrence, S. R., D. B. Preen, B. T. Dawson, J. Beilby, C. Goodman, and N. T. Cable. 1997. The effect of oral creatine supplementation on maximal exercise performance in competitive rowers. *Sports Medicine*, *Training and Rehabilitation* 7 (3-4):243–53. doi: 10.1080/15438629709512087.
- Lázaro da Silveira, C., T. S. Paiva de Souza, G. R. Batista, A. Targino de Araújo, J. C. Gomes da Silva, M. d S. Cirilo de Sousa, C. Marta, and N. D. Garrido. 2014. Is long term creatine and glutamine supplementation effective in enhancing physical performance of military police officers? *Journal of Human Kinetics* 43 (1):131–8. doi: 10.2478/hukin-2014-0098.
- Lee, D. K., J. In, and S. Lee. 2015. Standard deviation and standard error of the mean. *Korean Journal of Anesthesiology* 68 (3):220–3. doi: 10.4097/kjae.2015.68.3.220.
- LeLorier, J., G. Grégoire, A. Benhaddad, J. Lapierre, and F. Derderian. 1997. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. *New England Journal of Medicine* 337 (8):536–42. doi: 10.1056/NEJM199708213370806.
- Loon, L. J. C. V., R. Murphy, A. M. Oosterlaar, D. Cameron-Smith, M. Hargreaves, A. J. M. Wagenmakers, and R. Snow. 2004. Creatine supplementation increases glycogen storage but not GLUT-4 expression in human skeletal muscle. *Clinical Science* 106 (1):99–106. doi: 10.1042/CS20030116.
- McNaughton, L. R., B. Dalton, and J. Tarr. 1998. The effects of creatine supplementation on high-intensity exercise performance in elite performers. *European Journal of Applied Physiology* 78 (3):236–40. doi: 10.1007/s004210050413.
- Mesa, J. L. M., J. R. Ruiz, M. M. González-Gross, A. Gutiérrez Sáinz, and M. J. Castillo Garzón. 2002. Oral creatine supplementation and skeletal muscle metabolism in physical exercise. *Sports Medicine (Auckland, N.Z.)* 32 (14):903–44. doi: 10.2165/00007256-200232140-00003.
- Momaya, A., M. Fawal, and R. Estes. 2015. Performance-enhancing substances in sports: A review of the literature. Sports Medicine (Auckland, N.Z.) 45 (4):517–31. doi: 10.1007/s40279-015-0308-9.
- Murphy, A. J., M. L. Watsford, A. J. Coutts, and D. A. B. Richards. 2005. Effects of creatine supplementation on aerobic power and cardiovascular structure and function. *Journal of Science and Medicine in Sport* 8 (3):305–13. doi: 10.1016/S1440-2440(05)80041-6.
- Nelson, A. G., R. Day, E. L. Glickman-Weiss, M. Hegsted, J. Kokkonen, and B. Sampson. 2000. Creatine supplementation alters the response to a graded cycle ergometer test. *European Journal of Applied Physiology* 83 (1):89–94. doi: 10.1007/s004210000244.
- PEDro Scale for Randomized Controlled Trials. 2012. https://Pedro. Org.Au/.
- Poole, D. C., and A. M. Jones. 2017. Measurement of the maximum oxygen uptake Vo2max: Vo2 peak is no longer acceptable. *Journal* of Applied Physiology (Bethesda, Md.: 1985) 122 (4):997–1002. doi: 10.1152/japplphysiol.01063.2016.
- Preen, D., B. Dawson, C. Goodman, S. Lawrence, J. Beilby, and S. Ching. 2001. Effect of creatine loading on long-term sprint exercise

performance and metabolism. *Medicine and Science in Sports and Exercise* 33 (5):814–21. doi: 10.1097/00005768-200105000-00022.

- Reardon, T. F., P. A. Ruell, M. A. Fiatarone Singh, C. H. Thompson, and K. B. Rooney. 2006. Creatine supplementation does not enhance submaximal aerobic training adaptations in healthy young men and women. *European Journal of Applied Physiology* 98 (3):234–41. doi: 10.1007/s00421-006-0267-9.
- Reybrouck, T., J. Ghesquiere, M. Weymans, and A. Amery. 1986. Ventilatory threshold measurement to evaluate maximal endurance performance. *International Journal of Sports Medicine* 7 (1):26–9. doi: 10.1055/s-2008-1025730.
- Robinson, T. M., D. A. Sewell, A. Casey, G. Steenge, and P. L. Greenhaff. 2000. Dietary creatine supplementation does not affect some haematological indices, or indices of muscle damage and hepatic and renal function. *British Journal of Sports Medicine* 34 (4):284-8. doi: 10.1136/bjsm.34.4.284.
- "Scottish Intercollegiate Guidelines Network Sign 50: A Guideline Developer's Handbook. [(Accessed on 1 August 2019)] Available Online: http://www.Sign.Ac.Uk."
- Smith, A., D. Fukuda, E. Ryan, K. Kendall, J. Cramer, and J. Stout. 2011. Ergolytic/ergogenic effects of creatine on aerobic power. *International Journal of Sports Medicine* 32 (12):975-81. doi: 10.1055/s-0031-1283179.
- Sterkowicz, S., A. K. Tyka, M. Chwastowski, K. Sterkowicz-Przybycień, A. Tyka, and A. Klys. 2012. The effects of training and creatine malate supplementation during preparation period on physical capacity and special fitness in judo contestants. *Journal of the International Society of Sports Nutrition* 9 (1):41. doi: 10.1186/1550-2783-9-41.
- Tabata, I., K. Nishimura, M. Kouzaki, Y. Hirai, F. Ogita, M. Miyachi, and K. Yamamoto. 1996. Effects of moderate-intensity endurance and high-intensity intermittent training on anaerobic capacity and VO(2max). Medicine and Science in Sports and Exercise 28 (Nov):1327–30. doi: 10.1097/00005768-199610000-00018.
- Thomas, S. G., D. A. Cunningham, J. Thompson, and P. A. Rechnitzer. 1985. Exercise Training and "ventilation threshold" in elderly. *Journal* of Applied Physiology 59 (5):1472–6. doi: 10.1152/jappl.1985.59.5.1472.

- Thompson, C. H., G. J. Kemp, A. L. Sanderson, R. M. Dixon, P. Styles, D. J. Taylor, and G. K. Radda. 1996. Effect of creatine on aerobic and anaerobic metabolism in skeletal muscle in swimmers. *British Journal of Sports Medicine* 30 (3):222-5. doi: 10.1136/bjsm.30.3.222.
- Tyka, A. K., M. Chwastowski, T. Cison, T. Palka, A. Tyka, Z. Szygula, W. Pilch, M. Strzala, and M. Cepero. 2015. Effect of creatine malate supplementation on physical performance, body composition and selected hormone levels in spinters and long-distance runners. Acta Physiologica Hungarica 102 (1):114–22. doi: 10.1556/ APhysiol.102.2015.1.12.
- Van Loon, L. J. C., A. M. Oosterlaar, F. Hartgens, M. K. C. Hesselink, R. J. Snow, and A. J. M. Wagenmakers. 2003. Effects of creatine loading and prolonged creatine supplementation on body composition, fuel selection, sprint and endurance performance in humans. *Clinical Science* 104 (2):153–62. doi: 10.1042/ CS20020159.
- Villanueva, M. G., J. He, and E. T. Schroeder. 2014. Periodized resistance training with and without supplementation improve body composition and performance in older men. *European Journal of Applied Physiology* 114 (5):891–905. doi: 10.1007/ s00421-014-2821-1.
- "VO2 Max an Overview | ScienceDirect Topics." Accessed April 16, 2021. https://www.sciencedirect.com/topics/medicine-and-dentistry/ vo2-max.
- Wallimann, T., M. Tokarska-Schlattner, and U. Schlattner. 2011. The creatine kinase system and pleiotropic effects of creatine. *Amino Acids* 40 (5):1271–96. doi: 10.1007/s00726-011-0877-3.
- Wan, X., W. Wang, J. Liu, and T. Tong. 2014. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Medical Research Methodology* 14 (1):135 doi: 10.1186/1471-2288-14-135.
- Wasserman, K., B. J. Whipp, S. N. Koyl, and W. L. Beaver. 1973. Anaerobic threshold and respiratory gas exchange during exercise. *Journal of Applied Physiology* 35 (2):236–43. doi: 10.1152/jappl.1973.35.2.236.